Company Filing History:
Years Active: 2021
Title: Seung Yub Shin: Innovator in Therapeutic Protein Development
Introduction
Seung Yub Shin is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of therapeutic proteins, particularly through his innovative work on fusion proteins.
Latest Patents
Seung Yub Shin holds a patent for a fusion protein comprising a CCL3 variant. This invention provides a fusion protein that has improved in vivo persistency, protein stability, and pharmacological activity. More specifically, it includes a fusion protein that combines a CCL3 variant with an immunoglobulin Fc region, which can be used as a therapeutic agent for conditions such as lymphopenia, cancer, or infection. The CCL3 variant is characterized by the deletion of an N-terminal amino acid of a wild-type CCL3α or CCL3β, along with a substitution of an amino acid at a specific position.
Career Highlights
Seung Yub Shin is currently employed at Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on the development of innovative therapeutic solutions.
Collaborations
Some of his notable coworkers include Su Youn Nam and Jong Gyun Kim, who contribute to the collaborative efforts in research and development at Yuhan Corporation.
Conclusion
Seung Yub Shin's contributions to the field of therapeutic proteins exemplify the innovative spirit of modern science. His work on the CCL3 variant fusion protein highlights the potential for advancements in treating serious medical conditions.